Document is current

Any future updates will be listed below

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Crossref DOI link: https://doi.org/10.1007/s40123-020-00267-5

Published Online: 2020-06-18

Published Print: 2020-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark